Background. Treatment with cinacalcet improves the control of secondary hyperparathyroidism (SHPT) and the achievement of calcium and phosphorus targets. Most data come from subjects receiving cinacalcet after several years of dialysis treatment. We therefore compared the efficacy of treatment with cinacalcet and low doses of active vitamin D to flexible doses of active vitamin D alone for the management of SHPT in patients recently initiating haemodialysis.
Background. Treatment with cinacalcet improves the control of secondary hyperparathyroidism (SHPT) and the achievement of calcium and phosphorus targets. Most data come from subjects receiving cinacalcet after several years of dialysis treatment. We therefore compared the efficacy of treatment with cinacalcet and low doses of active vitamin D to flexible doses of active vitamin D alone for the management of SHPT in patients recently initiating haemodialysis.
Methods. This open-label trial randomized subjects (n = 309) with parathyroid hormone (PTH) >300 pg/mL on dialysis for 3-12 months to either cinacalcet with low-dose active vitamin D, if prescribed (cinacalcet); or usual care without cinacalcet (control). Randomized subjects were stratified by PTH at screening (300-450, >450-600, >600 pg/mL) and by the use of active vitamin D at enrolment. Treatment duration was 12 months, with primary efficacy endpoint (mean PTH reduction ≥30% from baseline) assessed at 6 months. Results. The mean [standard deviation (SD)] haemodialysis vintage at enrolment was 7.2 (2.7) months; 53% of subjects were not receiving active vitamin D at enrolment. There was a significant difference in the achievement of the primary endpoint (≥30% PTH reduction at 6 months) between cinacalcet-treated subjects and controls in both the entire cohort (63 versus 38%; n = 304; P < 0.0001) and the subgroup of subjects not receiving active vitamin D at enrolment (70 versus 44%; n = 161; P < 0.01). Hypocalcaemia and gastrointestinal adverse events were more commonly observed in cinacalcet-treated subjects. Conclusions. These results indicate that cinacalcet with lowdose active vitamin D, if prescribed, provides a more effective treatment approach than usual care without cinacalcet for SHPT in incident haemodialysis patients, even in relatively treatment-naive patients.
I N T R O D U C T I O N
Secondary hyperparathyroidism (SHPT), a common consequence of chronic kidney disease (CKD), begins to develop well before patients reach end-stage kidney disease and are started on maintenance dialysis. Most patients with CKD-4 have elevated levels of parathyroid hormone (PTH) [1, 2] . Substantial elevations in PTH are also noted in incident patients shortly after initiation of dialysis [3, 4] . Subsequently, SHPT severity appears to worsen over time in patients on dialysis, as shown by a progressive increase in mean PTH levels [5] .
Initial therapy for SHPT in patients on dialysis usually includes phosphate binders and active vitamin D analogues. Cinacalcet (Sensipar ® /Mimpara ® ), when utilized, is often initiated later in the course of SHPT in patients who have failed to respond adequately to earlier treatment. Such patients often have markedly elevated PTH levels, as well as significant biochemical alterations such as hypercalcaemia and/or hyperphosphataemia, which limit the use of active vitamin D. Multiple studies have demonstrated that treatment with cinacalcet, when added to regimens that can include vitamin D and phosphate binders, improves the control of SHPT as well as the achievement of recommended target values for serum calcium and phosphorus [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] . These trials did not exclude incident dialysis patients; however, most subjects had been on dialysis for an extended time with a mean dialysis vintage ranging from 3 to 6 years.
This study evaluated the efficacy and safety of treatment with cinacalcet and low doses of active vitamin D compared with usual care without cinacalcet for the management of SHPT in patients who had recently been initiated on maintenance haemodialysis.
M AT E R I A L S A N D M E T H O D S
This multicentre, phase 4, international, randomized and open-label trial enrolled adults with SHPT and CKD-5D in whom haemodialysis was initiated within 3-12 months before enrolment (Eudract 2008-004558-34). Subjects had a mean intact PTH (second-generation assay) >300 pg/mL or a biointact PTH (third-generation assay) >160 pg/mL and a mean albumin-corrected total serum calcium (serum calcium) of ≥8.4 mg/dL, were cinacalcet naive; and, for ≥30 days prior to the screening phase, had not been receiving active vitamin D or had been on a stable dose. Patients were excluded if they had severe uncontrolled SHPT (PTH >800 pg/mL or biointact PTH >430 pg/mL) despite active vitamin D therapy; had undergone parathyroidectomy within 6 months of screening or parathyroidectomy was anticipated within 6 months after randomization; or were scheduled for renal transplant within the study period. All subjects provided written informed consent. The study protocol was approved by local ethics committees.
Subjects were screened at two visits at least 2 days apart to collect the two PTH and serum calcium values that provided the enrolment data. Subjects receiving active vitamin D at enrolment underwent a 4-week washout, after which all eligible subjects were centrally randomized in a 1:1 ratio to cinacalcet plus low-dose active vitamin D (if prescribed; cinacalcet group) or usual care with flexible doses of active vitamin D as determined by practice guidelines and physician preference (control group). Low-dose active vitamin D was defined as intravenous (IV) (≤calcitriol 0.5 µg, alfacalcidol, doxercalciferol 1 µg or paricalcitol 2 µg per dialysis visit) or oral treatment (calcitriol 0.25 µg, paricalcitol 1 µg or alfacalcidol 0.25 µg per day). Randomization was stratified by PTH level at screening (300-450, >450-600 or >600 pg/mL) and by use of vitamin D at enrolment (none, oral or IV). The randomization scheme for the study was generated by Amgen and loaded into an interactive voice recognition system (IVRS). Physicians received a randomization number and assigned treatment for each eligible subject by calling the IVRS. Subjects in both groups continued to receive phosphate binders at the discretion of their physician.
Following randomization, subjects completed a 22-week dose titration phase with visits every 2 weeks (Figure 1 ). Subjects in the cinacalcet arm received a cinacalcet starting dose of 30 mg once daily, adjusted at Weeks 4, 8, 12, 16 and 20 as required; those receiving active vitamin D at enrolment received it at low doses at baseline; for all subjects, it could be initiated or adjusted as indicated by serum levels of PTH, calcium and phosphorus. Subjects in the control arm continued to receive their previous therapy; active vitamin D dose could be adjusted at any time during the study as indicated by serum levels of PTH, calcium and phosphorus. During the efficacy assessment phase (EAP) at Month 6 (Weeks 22-26), PTH, serum calcium and phosphorus levels were determined at three visits. During the second EAP at Month 12 (Weeks 48-52), this was repeated after a 22-week maintenance phase. Treatment with cinacalcet and active vitamin D was stopped at 52 weeks in both groups and PTH levels were re-assessed after a 4-week washout.
The primary endpoint was a reduction in the mean PTH of ≥30% from baseline at 6 months (i.e. during the EAP at Month 6). Secondary endpoints included: ≥30% reduction in the mean PTH from baseline at 12 months (i.e. during the EAP at Month 12) and at both 6 and 12 months; achievement of study-specified treatment targets for PTH (mean ≤300 pg/ mL), calcium (mean <10.2 mg/dL) and phosphorus (mean <5.5 mg/dL) at 6 and 12 months and subject incidences of elevated serum calcium (≥10.2 mg/dL), elevated phosphorus (≥5.5 mg/dL) and hypocalcaemia (≤7.5 and <8.4 mg/dL). Safety endpoints included the frequency, severity and reported relationship to treatment of adverse events (AEs) and serious AEs (SAEs) throughout the study. Investigators were instructed to report an AE related to hypocalcaemia if a drop in serum calcium necessitated a change in medical therapy.
Statistical analysis
The study was powered to detect the differences between the treatment groups in the primary endpoint, with expected response rates for the cinacalcet (65%) and control groups (45%) based on the analyses of a similar patient population in the phase 3b studies OPTIMA and TARGET and the COSMOS cohort study. Sample size calculations were based on a twosided continuity-corrected χ 2 test of equal proportions, assuming a significance level of 0.05 and power of 90%, and allowed for a drop-out rate of 8% for subjects enrolled but not randomized and for subjects randomized but not eligible for inclusion into the full analysis set.
All efficacy analyses were intention-to-treat based on the full analysis set, which comprised all randomized subjects with at least one PTH value after study day 1. Subjects were analysed according to randomized treatment group. Missing data were imputed using the last observation carried forward method, with appropriate sensitivity analyses including observed data analysis and non-responder imputation. The primary endpoint was based on the mean of all available PTH measurements in the EAP at Month 6. Analysis of PTH reduction ≥30% at 12 months and PTH ≤300 pg/mL at 6 and 12 months was adjusted for multiple comparisons (correlation-based Dubey and Armitage-Parmar method). Means are presented with SD. Comparisons between treatment groups for the primary and selected secondary endpoints were made using the Cochran-Mantel-Haenszel test, including stratification factors; for other secondary endpoints, differences and 95% confidence intervals (95% CI) were estimated and the P-values calculated based on the analysis of covariance (ANCOVA) or, if model assumptions were not met, then using ANCOVA after appropriate data transformations.
Safety analyses were based on the safety analysis set (all randomized subjects and, for the cinacalcet group, subjects who received ≥1 dose of cinacalcet). Subjects were analysed according to the randomized treatment group but if any subject randomized to the control group received cinacalcet throughout the study, they were included in the cinacalcet group for safety analyses. Incidence of all AEs was summarized by system organ class and preferred term using descriptive statistics. Odds ratios (ORs) and 95% CIs are also provided for AEs occurring in at least 5% of subjects in either treatment group.
R E S U LT S
This study was conducted between February 2009 and July 2011. Of the 313 patients who met the inclusion criteria and were enrolled into the study, 309 were randomized to treatment and 304 were included in the full analysis set ( Figure 2 ). Of all the randomized subjects, 161 (53%) were not on active vitamin D at enrolment. In addition, 48 (31%) cinacalcettreated subjects and 20 (13%) controls did not receive active vitamin D during the treatment phase, at the discretion of the investigator. All subjects in the cinacalcet group received at least one dose of cinacalcet during the study. Due to an administrative error, one subject in the control group received cinacalcet throughout the study; this subject was included in the control group for efficacy analyses and the cinacalcet group for safety analyses. In addition, eight (5%) control subjects received non-study cinacalcet at some point during the treatment phase. Study results are reported separately for the entire cohort and the subgroup not receiving active vitamin D at enrolment. Subjects who did not receive active vitamin D during the treatment phase were not excluded from other analyses.
Entire cohort
Baseline characteristics were well balanced between the treatment arms ( Table 1 ), except that the mean PTH was higher in the cinacalcet than control group. The mean haemodialysis vintage at enrolment was 7.2 (2.7) months in the entire cohort.
A significantly greater proportion of subjects achieved the primary endpoint (≥30% PTH reduction from baseline at 6 months) in the cinacalcet than control group (63 versus 38%, P < 0.001) ( Table 2 ). The difference in the achievement of ≥30% PTH reduction from baseline remained significant at 12 months and at both 6 and 12 months. The results were consistent using the observed data and non-responder imputation sensitivity analyses. The results favouring cinacalcet were observed across all the PTH strata ( Figure 3 ). At 6 months and 12 months, a greater proportion of subjects in the cinacalcet than control group achieved a PTH ≤300 pg/mL, statistically significant at 6 months but not at 12 months; more also had PTH <150 pg/mL ( Table 2 ). The mean PTH was significantly lower ( Figure 4 ) and the mean percentage reduction in PTH was greater (Table 2) in the cinacalcet than control group at 6 months and these differences remained significant at 12 months. At Week 56, 4 weeks after treatment discontinuation, PTH returned to near baseline levels in both the cinacalcet and control groups ( Figure 4 ).
The mean serum calcium levels were significantly lower in the cinacalcet than control group at 6 and 12 months 
O R I G I N A L A R T I C L E
C i n a c a l c e t i n i n c i d e n t h a e m o d i a l y s i s s u b j e c t s w i t h S H P T (Table 2; Figure 5A ). There was no difference in the proportion of subjects in the two groups achieving serum calcium <10.2 mg/dL during efficacy assessment. More subjects in the control than cinacalcet group had at least one elevated serum calcium value during the treatment phase (≥10.2 mg/dL; 37 versus 24%; P = 0.010). More subjects in the cinacalcet than control group had at least one low serum calcium value (Table 2 ). In a post hoc analysis, sustained hypocalcaemia (two consecutive serum calcium values ≤7.5 mg/dL) was more common in the titration phase than in the maintenance phase ( Table 2) .
The proportion of subjects achieving serum phosphorus <5.5 mg/dL was not different in the two groups during efficacy assessment (Table 2) . However, at 6 months, mean serum phosphorus was significantly lower in the cinacalcet than control group ( Figure 5B , Table 2 ). There was no difference in the frequency of elevated phosphorus values (≥5.5 mg/dL). The total mean dose of calcium-containing phosphate binders increased from baseline to Week 52 in the cinacalcet group and to a lesser extent in the control group (Table 2, Figure 6C) .
A total of 20 control subjects did not receive vitamin D sterols during the treatment phase. The baseline mean (SD) iPTH, serum calcium and serum phosphorus in these 20 subjects were 520.6 (287.3) pg/mL, 9.02 (0.44) mg/dL and 5.70 (1.81) mg/dL, respectively. At 6 months, the respective values were 494.1 (95% CI: 328.1, 660.1) pg/mL, 9.18 (95% CI: 8.93, 9.44) mg/dL and 5.81 (95% CI: 4.98, 6.64) mg/dL. The results for achievement of the primary endpoint remained significant when these 20 control subjects who did not receive vitamin D sterols were excluded from the analysis (40 versus 63% in the entire cinacalcet arm; P < 0.001). Figure 6 also shows the mean doses of cinacalcet (6A) and active vitamin D (6B) throughout the study, including zero doses for subjects with dose withheld at that time point. Subjects in the lowest PTH stratum at enrolment required the lowest doses of cinacalcet (treatment period mean: 36.1 versus 42.1 and 52.2 mg/day for the middle and highest PTH strata). The percentage of subjects with cinacalcet therapy withheld at any study visit ranged from 12% at Week 6 to 28% at Week 52. The use of nutritional vitamin D in the treatment phase was minimal (∼17% of all subjects) and did not differ between treatment groups.
The overall subject incidence of treatment-emergent AEs, shown with OR (95% CI), was similar in the cinacalcet and Table S2 ). Most of the AEs related to hypocalcaemia were mild, although one subject terminated treatment with cinacalcet after an AE of hypocalcaemia. Investigators assessed relatedness of AEs to cinacalcet or vitamin D therapy. The incidence of AEs reported by investigators as possibly related to study drug were 39% for cinacalcet, and 6 and 2% for vitamin D in the cinacalcet and control groups, respectively. Of these, the most common cinacalcet-related AEs were nausea (14%), hypocalcaemia (14%), vomiting (12%), diarrhoea (5%), muscle spasms (3%), upper abdominal pain (2%), 
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abdominal pain (1%) and decreased blood calcium (1%) and the most common vitamin D-related AEs were hypocalcaemia (1%), hypercalcaemia (1%) and hyperphosphataemia (1%) in the cinacalcet group and increased blood calcium (1%) in the control group. SAEs occurred in a higher percentage of patients in the cinacalcet (46%, 72 subjects) than control group (34%, 52 subjects) (Supplementary Table S2 ), although none were reported as related to treatment and no SAEs of Adjusted mean (95% CI). b n (%). c No formal statistical comparison. *P < 0.05, **P < 0.01, ***P ≤ 0.001, ****non-significant (P ≥ 0.05) versus control group.
F I G U R E 3 : Subjects achieving ≥30% reduction in PTH from baseline at 6 months, by randomization stratification. *Significant between-group difference (P < 0.05). † This is the 'no' stratum from the 'active vitamin D use at enrolment' section.
O R I G I N A L A R T I C L E
P. Ureña-Torres et al. hypocalcaemia were reported. Two subjects withdrew from the study due to parathyroidectomy, one in the cinacalcet group (in Week 17) and the other in the control group (in Week 45). The incidence of fatal AEs was 5% in both the cinacalcet (n = 8) and control groups (n = 7) (Supplementary Table S3 Subgroup analysis: subjects not receiving vitamin D at enrolment Subjects who were not receiving active vitamin D therapy at enrolment provide an opportunity to assess the efficacy of cinacalcet in relatively treatment-naive patients. The results in this subgroup were similar to those in the entire cohort (Table 2, Figure 3 ). At baseline, the PTH levels were modestly higher in this subgroup than in the entire cohort (data not shown).
As in the entire cohort, a significantly greater proportion of subjects achieved the primary endpoint in the cinacalcet than control group (Table 2, Figure 3) . A greater proportion of subjects in the cinacalcet than control group achieved a PTH ≤300 pg/mL, significant at 6 months but not at 12 months ( Table 2 ). The percentage of subjects with at least one elevated serum calcium value (≥10.2 mg/dL) was similar in the cinacalcet and control groups (26 versus 32%). As in the entire cohort, hypocalcaemia was more common in the titration phase than in the maintenance phase ( Table 2 ). The incidence of low serum calcium levels was similar to that in the entire cohort of cinacalcet-treated subjects. There was no difference in the mean serum phosphorus in the cinacalcet and control groups.
The subject incidence of treatment-emergent AEs and SAEs in this subgroup analysis mirrored those in the entire cohort.
D I S C U S S I O N
Our results demonstrate that a cinacalcet-based regimen with low-dose vitamin D (if prescribed) is more effective than usual Table 3 . Number (%) of subjects with treatment-emergent adverse events occurring in ≥5% of subjects in either treatment group
Entire cohort
Odds ratio (95% CI) 
O R I G I N A L A R T I C L E
C i n a c a l c e t i n i n c i d e n t h a e m o d i a l y s i s s u b j e c t s w i t h S H P T care based on flexible doses of active vitamin D alone in decreasing PTH levels in patients with SHPT recently initiating haemodialysis treatment. A higher percentage of subjects achieved the primary endpoint of PTH reduction ≥30% in the cinacalcet group across the spectrum of severity of SHPT, irrespective of the prior use of vitamin D. Cinacalcet treatment led to modest reductions in both calcium and phosphorus levels, consistent with results from previous studies [7, 9, 17] . Previous studies of cinacalcet have been underpowered to assess efficacy in incident dialysis patients [7] [8] [9] . This 12-month study with two EAPs is one of the longest randomized cinacalcet trials to date [7, 9, 18 ]. Stratification by both PTH level and active vitamin D use at enrolment made it possible to assess efficacy in subjects with a wide range of disease severity including those not previously treated for SHPT.
While most studies evaluating the efficacy of cinacalcet have enrolled subjects who had uncontrolled SHPT despite receiving the standard of care, including active vitamin D [7] [8] [9] [10] [11] [12] 19] , in this study, the previous use of active vitamin D was not an entry criterion and 53% of the subjects were not receiving active vitamin D at enrolment. This allowed the study to uniquely evaluate a large number of relatively treatment-naive subjects, avoiding the bias of response or non-response to previous SHPT therapy ('carry-over effect'). Our results demonstrate that this subgroup not receiving vitamin D at enrolment had a comparable efficacy and safety profile to the entire cohort of cinacalcet-treated subjects.
Baseline haemodialysis vintage in this study was considerably shorter than in previous studies evaluating the treatment of SHPT [7, 9, 18, 20, 21] . Incident dialysis patients have unique characteristics that distinguish them from those surviving on dialysis for longer periods of time. A greater preservation of residual renal function in incident subjects could impact calcium and phosphorus regulation. Parathyroid hyperplasia might be less severe, which could affect the dosages of therapies required for the control of SHPT [22] . Severe nodular hyperplasia in long-term dialysis patients is associated with decreased expression of vitamin D and calcium-sensing receptors, which could lead to treatment resistance [23] .
Cinacalcet dosages required in this study of incident haemodialysis subjects were generally low despite the fact that ∼25% of the population had relatively severe SHPT with baseline PTH levels >600 pg/mL. The mean cinacalcet dose in this study of 42 mg/day is lower than the dosage reported in other cinacalcet trials that included subjects of greater dialysis vintage with a comparable spectrum of SHPT severity [9, 19] . Thus, the use of cinacalcet earlier in the time course of the disease process may allow for lower dosage requirements than in dialysis patients of higher vintage with similar PTH levels. Within this and other cinacalcet trials in SHPT, using cinacalcet at lower levels of pre-treatment PTH was also noted to result in lower dosage requirements.
A unique aspect of this study was the assessment of PTH levels after a 4-week washout of SHPT therapy at the end of the study. The PTH level noted while not on therapy is thought to correlate with parathyroid gland mass [24] . After post-treatment washout of active vitamin D and cinacalcet in both groups, there was a rapid rise of PTH levels to values approaching those at baseline. This suggests that neither treatment approach over a 12-month period had an impact on the degree of parathyroid hyperplasia and supports the concept that SHPT in dialysis patients is a chronic disease that is best managed with long-term uninterrupted therapy. This is not surprising in view of the very low apoptotic rate of parathyroid cells and does not exclude the possibility that more prolonged intervention might promote reversal of the hyperplastic process [25] .
All subjects in the cinacalcet group received at least one dose of cinacalcet during the treatment phase and ∼80% of subjects were receiving cinacalcet at any of the study visits (ranging from 88% at Week 6 to 72% at Week 52). Cinacalcet dosages were withheld most commonly in response to low PTH and/or low calcium. The use of vitamin D in both treatment groups was at the discretion of the investigator, though guidance was provided to investigators for vitamin D dosing. The use of vitamin D at the initiation of treatment was to be based on the pre-enrolment vitamin D usage in both arms of the study. Thereafter, in the cinacalcet arm, the initial low dosages of vitamin D could be increased or vitamin D could be initiated based on serum calcium levels. In the control arm, vitamin D was to be initiated and/or titrated according to standard treatment guidelines effective at each centre. In fact, 31% of the subjects in the cinacalcet arm and 13% of the subjects in the control arm never received vitamin D during the treatment phase of the study. Of the 20 subjects in the control arm who never received active vitamin D during the treatment phase, 16 had either persistent hyperphosphataemia and/or PTH levels persistently <300 pg/mL. Of the other four control subjects who never received active vitamin D, two ended the study very early in the course (<60 days) and the other two had intermittent hyperphosphataemia. Overall, this suggests that hyperphosphataemia or low PTH levels after initiation of the treatment phase of the study may have prompted investigators to withhold vitamin D treatment in this subset of control subjects.
The mean serum calcium level was significantly lower in the cinacalcet than control group at 6 months. Calcium levels were lowest shortly after initiation of cinacalcet then rose progressively. The dose of calcium-containing binders increased throughout the course of the study in cinacalcet-treated subjects and many subjects in the cinacalcet arm initiated active vitamin D during the titration phase of the study. These changes in concomitant medications most likely accounted for the increase in serum calcium over the course of the study as doses of cinacalcet remained steady. The subject incidence of AEs of hypocalcaemia was higher in the cinacalcet than the control group, with an OR (95% CI) of 29 (3.9, 220.1). Although low serum calcium levels were common in the cinacalcet group, AEs of hypocalcaemia were generally mild and only one subject terminated treatment with cinacalcet following an AE of hypocalcaemia. However, the subject incidence of AEs of hypocalcaemia with cinacalcet was higher (16%) than those reported in previous studies (0.5-7%; various definitions) [7] [8] [9] 17] . The higher incidence of hypocalcaemia AEs in this study than in previous cinacalcet trials may in part be due to the lower baseline calcium levels in these incident dialysis subjects. Mean calcium at baseline was 9.2 mg/dL for the entire cohort, compared with 9.9 mg/dL in the pooled phase III studies [19] . The incidence of hypocalcaemia in cinacalcet-treated subjects was similar in the entire cohort and those not receiving vitamin D at enrolment.
Other AEs possibly related to cinacalcet treatment were mostly gastrointestinal events. The subject incidences of nausea and vomiting in the cinacalcet group were about twice those in the control group, with ORs (95% CI) of 2.22 (1.14 and 4.33) and 2.11 (1.06 and 4.20), respectively. This was similar to the incidence of adverse gastrointestinal events reported in previous trials of cinacalcet. Although SAEs were more common in the cinacalcet than control group, none were considered related to cinacalcet and the types of events reported are common in a haemodialysis population. Despite the greater reduction in PTH in subjects treated with cinacalcet, only modest reductions in BALP (1 and 8% at Weeks 26 and 52) were observed, which were no greater than those observed in the control arm (14 and 17%, respectively). It is thus uncertain whether the greater suppression of PTH associated with cinacalcet treatment was also associated with a greater decrease in bone turnover. Block et al. [14] reported 35 and 4% decreases in the median BALP values at Week 26 with cinacalcet and control, respectively, in combined results from two studies and Belozeroff et al. [26] reported modest decreases in serum alkaline phosphatase at Weeks 26 and 52 with cinacalcet compared with modest increases in the control arm in combined results from four studies (including those in the Block et al. paper). These differences could be due to the differences in dialysis vintage (7 months in the current study versus 72 [14] and 47 months [26] ), baseline disease severity (serum PTH levels of 536 versus 643 [14] and 601 pg/mL [26] ), the use of serum bone-specific versus total alkaline phosphatase levels or the different doses of active vitamin D in cinacalcet-treated subjects (4.5 versus 15 μg/week [26] ).
The current study has certain limitations. This was an open-label study and neither investigators nor subjects were blinded to treatment modality. Cinacalcet was dosed by forced titration. Active vitamin D administration and dosage was at the discretion of the investigator in each treatment arm and, as previously stated, a subset of subjects in both treatment arms did not receive active vitamin D during the treatment phase of the study. In addition, a small subset of control subjects received some non-study cinacalcet at some point during the study which, if anything, would have been expected to weigh against any beneficial effect of cinacalcet on the primary study outcome. The observed differences could have been influenced by differing attitudes of investigators towards increasing active vitamin D dose as there was not a forced dose titration in the control arm. More aggressive dosing of vitamin D in the control arm might have resulted in lower PTH levels but would probably also have amplified observed differences in calcium and phosphorus control between the two treatment arms.
Both cinacalcet and control treatment arms demonstrated a reduction in PTH compared with baseline. However, a cinacalcet-based regimen reduced PTH to a significantly greater extent than flexible doses of vitamin D without cinacalcet.
This difference was consistent across all PTH strata, was sustained throughout the 12 months of the study and was independent of prior use of active vitamin D. Treatment with cinacalcet was associated with lower calcium and phosphorus levels than treatment with active vitamin D (if prescribed) alone. As expected, the incidence of hypocalcaemia was greater in subjects receiving cinacalcet, although hypocalcaemia rarely led to discontinuation of treatment and calcium levels increased over the course of the study related to increased use and dosing of active vitamin D sterols and calcium-containing phosphate binders. The modest reduction in phosphorus levels associated with cinacalcet treatment in this study is thought to be due to a decrease in PTH-mediated release of phosphorus from bone mineral and has been observed in other trials utilizing cinacalcet in the treatment of SHPT in dialysis patients [8, 9 , Cooper et al., J Am Soc Nephrol 2011;22:401A]. Our results suggest that a cinacalcet-based regimen with or without low doses of active vitamin D can be considered effective initial treatment for SHPT in incident haemodialysis patients, with a similar safety profile to that reported from other studies of cinacalcet. The control of SHPT in the incident haemodialysis population can be achieved with relatively low doses of cinacalcet. The rebound of PTH to near pre-treatment levels after 1 year of SHPT therapy confirms both the chronic nature of SHPT in the dialysis population and the need for long-term uninterrupted therapy regardless of treatment modality. Longer term studies with calcimimetic agents are under way to assess their potential effects on disease progression including the impact on risk of parathyroidectomy [27] .
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